AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Cloudflare Forecasts Strong Revenue Growth as AI Fuels Cloud Services Demand 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
MENLO PARK, Calif., Nov. 09, 2017 -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report financial results for the fourth quarter and fiscal year ended September 30, 2017 on Thursday, November 16, 2017 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and report on recent progress.
Conference Call and Webcast Details
Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 4879369. The conference call will also be available via a live audio webcast which may be accessed here, or by visiting the Investors section of Corium's website at http://ir.coriumgroup.com/events.cfm. The webcast will be archived on the Corium website for two weeks following the presentation.
About Corium
Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. In addition to its proprietary Alzheimer's program, the company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit www.coriumintl.com.
Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.
Source: Corium
Investor and Media Contact:
SMP Communications
Susan Pietropaolo
[email protected]
(201) 923-2049
